APDN vs. SPCB, GWAV, JCSE, CRKN, AREB, MOB, LGMK, VIEW, DGLY, and ADN
Should you be buying Applied DNA Sciences stock or one of its competitors? The main competitors of Applied DNA Sciences include SuperCom (SPCB), Greenwave Technology Solutions (GWAV), JE Cleantech (JCSE), Crown ElectroKinetics (CRKN), American Rebel (AREB), Mobilicom (MOB), LogicMark (LGMK), View (VIEW), Digital Ally (DGLY), and Advent Technologies (ADN). These companies are all part of the "industrial products" sector.
SuperCom (NASDAQ:SPCB) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap industrial products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
SuperCom received 54 more outperform votes than Applied DNA Sciences when rated by MarketBeat users. However, 59.39% of users gave Applied DNA Sciences an outperform vote while only 58.77% of users gave SuperCom an outperform vote.
Applied DNA Sciences has a consensus target price of $30.00, suggesting a potential upside of 700.00%. Given SuperCom's higher possible upside, analysts clearly believe Applied DNA Sciences is more favorable than SuperCom.
47.8% of SuperCom shares are held by institutional investors. Comparatively, 22.2% of Applied DNA Sciences shares are held by institutional investors. 18.3% of SuperCom shares are held by company insiders. Comparatively, 10.3% of Applied DNA Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
SuperCom has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Applied DNA Sciences has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.
SuperCom has a net margin of -9.79% compared to SuperCom's net margin of -80.14%. Applied DNA Sciences' return on equity of 91.58% beat SuperCom's return on equity.
SuperCom has higher revenue and earnings than Applied DNA Sciences. SuperCom is trading at a lower price-to-earnings ratio than Applied DNA Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, SuperCom and SuperCom both had 2 articles in the media. Applied DNA Sciences' average media sentiment score of 0.50 beat SuperCom's score of 0.49 indicating that SuperCom is being referred to more favorably in the media.
Summary
SuperCom beats Applied DNA Sciences on 10 of the 16 factors compared between the two stocks.
Get Applied DNA Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied DNA Sciences Competitors List
Related Companies and Tools
